Status:
NOT_YET_RECRUITING
Use of QRX-3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
Lead Sponsor:
Ebima Clifford Okundaye
Conditions:
Acute Renal Failure (ARF)
Acute Tubular Necrosis
Eligibility:
All Genders
10-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
Eligibility Criteria
Inclusion
- Hospitalized patients
- presence of Acute renal failure
- Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of \>2%
- willingness to participate
Exclusion
- High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status
Key Trial Info
Start Date :
August 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT07161843
Start Date
August 30 2025
End Date
February 1 2027
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neukidney Inc
Rosharon, Texas, United States, 77583